-+ 0.00%
-+ 0.00%
-+ 0.00%

NRx Pharmaceuticals Q3 net loss narrows 63% to $2.2 million

PUBT·11/17/2026 12:19:38
Listen to the news
NRx Pharmaceuticals Q3 net loss narrows 63% to $2.2 million
  • NRx Pharmaceuticals’ third-quarter 2026 net loss narrowed 63% year over year to $2.2 million.
  • Net patient service revenue rose to $1.2 million, reflecting growth at HOPE Therapeutics clinics.
  • Selling, general and administrative expenses more than doubled to $6.6 million, primarily reflecting preparations for the preservative-free ketamine launch.
  • FDA approved preservative-free ketamine in October 2026; commercial sales began the week of November 9.
  • Product shipments are scheduled to begin no later than January 2027; management targets profitability in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170718PRIMZONEFULLFEED9879339) on November 17, 2026, and is solely responsible for the information contained therein.